Skip to Content
Merck
CN
All Photos(1)

Key Documents

View All Documentation

Safety Information

SML2769

Sigma-Aldrich

ASS234

≥98% (HPLC)

Synonym(s):

N,1-Dimethyl-5-[3-[1-(phenylmethyl)-4-piperidinyl]propoxy]-N-2-propyn-1-yl-1H-indole-2-methanamine, N-[[5-[3-(1-Benzylpiperidin-4-yl)propoxy]-1-methyl-1H-indol-2-yl]methyl]-N-methyl-2-propyn-1-amine

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C29H37N3O
CAS Number:
1334106-34-1
Molecular Weight:
443.62
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

CN1C(CN(CC#C)C)=CC2=C1C=CC(OCCCC(CC3)CCN3CC4=CC=CC=C4)=C2

InChI key

ADCBAOTWERXLAP-UHFFFAOYSA-N

Biochem/physiol Actions

ASS234 is a brain-penetrant and orally active multi-target small molecule (MTSM) against (acetyl & butyryl) cholinesterases (hAChE/hBuChE IC50 = 0.81/1.82 μM), monoamine oxidases (hMAO-A/B IC50 = 0.27/120 nM), histamine H3 receptor (hH3R Ki = 84.2 nM; hH4R Ki >10 μM) and sigma-1/2 receptors (hS1R/rS2R = 2.82/50.3 nM). ASS234 exhibits antioxidative and neuroprotective effects in SH-SY5Y cultures (5 μM) and demonstrates therapeutic efficacy in neurodegerative disease models in vivo via sc. (0.62 mg/kg/d mice; 5 mg/kg rats), ip. (1 mg/kg mice) or po. (1 & 10 mg/kg mice).
Orally active, brain-penetrant, multi-target ligand against MAO-A/B, cholinesterases, H3 & sigma receptors with neuroprotective and pro-cognitive efficacy in vivo.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Regulatory Information

新产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000102377
0000102376
0000098863

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mari Paz Serrano et al.
Journal of psychiatry & neuroscience : JPN, 42(1), 59-69 (2016-09-17)
The heterogeneity of Alzheimer disease requires the development of multitarget drugs for treating the symptoms of the disease and its progression. Both cholinergic and monoamine oxidase dysfunctions are involved in the pathological process. Thus, we hypothesized that the development of
Upregulation of Antioxidant Enzymes by ASS234, a Multitarget Directed Propargylamine for Alzheimer's Disease Therapy.
Eva Ramos et al.
CNS neuroscience & therapeutics, 22(9), 799-802 (2016-07-07)
Óscar M Bautista-Aguilera et al.
Journal of medicinal chemistry, 61(15), 6937-6943 (2018-07-04)
Contilisant, a permeable, antioxidant, and neuroprotectant agent, showing high nM affinity at H3R and excellent inhibition of the monoamine oxidases and cholinesterases, is an affine and selective S1R agonist in the nanomolar range, based on the binding affinity and functional
Óscar M Bautista-Aguilera et al.
Angewandte Chemie (International ed. in English), 56(41), 12765-12769 (2017-09-02)
The therapy of complex neurodegenerative diseases requires the development of multitarget-directed drugs (MTDs). Novel indole derivatives with inhibitory activity towards acetyl/butyrylcholinesterases and monoamine oxidases A/B as well as the histamine H3 receptor (H3R) were obtained by optimization of the neuroprotectant
Javier Del Pino et al.
ACS chemical neuroscience, 9(12), 2880-2885 (2018-07-27)
There is clear evidence that neuroinflammation plays a crucial role in the pathogenesis of Alzheimer's disease. Consequently, modulating the inflammatory environment in brain has become a powerful and attractive strategy to deal with Alzheimer's disease physiopathology. In spite of the
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service